Novartis AG stock (CH0012005267): pharma heavyweight digests Sandoz spin-off and eyes next growth wave

Novartis AG remains in focus after digesting the Sandoz spin-off and updating investors on its focused medicines strategy, while the stock continues to trade near multi?year highs on the NYSE.

Novartis AG is back in the spotlight as the Swiss healthcare group advances its focused medicines strategy following the spin-off of generics unit Sandoz and updates investors on its innovation-driven pipeline and margin ambitions, while its American depositary shares (ADS) on the NYSE trade close to recent highs, according to Novartis investor news as of 05/2026 and MarketBeat as of 06/08/2026.

As of: 09.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Basel, Switzerland
• Core markets: Global prescription medicines with strong US exposure
• Key revenue drivers: Innovative prescription drugs and oncology therapies
• Home exchange/listing venue: SIX Swiss Exchange and NYSE (ticker: NVS)
• Trading currency: Swiss franc on SIX, US dollar on NYSE

Novartis AG: core business model

Novartis AG is one of the largest global healthcare companies, focusing on patented prescription medicines across areas such as cardiovascular, immunology, neuroscience and oncology, while increasingly positioning itself as a “pure-play” innovative medicines company after completing the spin-off of its Sandoz generics division in 2023, according to Novartis annual report 2023 as of 02/29/2024.

The group reports mainly through its Innovative Medicines business, which is organized around therapeutic areas and focuses on high-value, patent-protected therapies that target large and specialty patient populations, according to Novartis strategy overview as of 02/29/2024.

Management has communicated a strategy built on four pillars: focus on high-value medicines, strengthen the company’s core therapeutic platforms, improve operational efficiency and capital allocation, and embed data and digital tools in research and commercial operations, according to Novartis strategy presentation as of 09/2023.

After the Sandoz separation, Novartis emphasizes a leaner structure with a more concentrated portfolio of higher-margin assets, targeting improved core operating margins over the medium term as it scales key brands and optimizes its cost base, according to Novartis spin-off materials as of 09/15/2023.

The company’s business model relies on a mix of blockbuster drugs with multi-billion dollar annual revenue potential and a pipeline of earlier-stage assets that can replenish growth as existing medicines approach patent expiry, according to Novartis pipeline overview as of 05/2026.

Novartis invests heavily in research and development to sustain this model, with R&D spend equivalent to a significant double-digit percentage of sales in 2023, as disclosed in the company’s annual report where it highlights ongoing clinical programs across multiple late-stage assets, according to Novartis annual report 2023 financial review as of 02/29/2024.

In addition to developing medicines in-house, Novartis routinely uses targeted acquisitions, licensing deals and partnerships to access new technologies and broaden its pipeline, particularly in cell and gene therapies and in next-generation oncology approaches, according to Novartis media releases as of 2024.

Main revenue and product drivers for Novartis AG

Novartis’ revenue base is built on a portfolio of established and emerging brands, with cardiovascular drug Entresto, psoriasis and psoriatic arthritis treatment Cosentyx, and multiple sclerosis therapy Kesimpta among the largest contributors in recent years, according to Novartis performance overview 2023 as of 02/29/2024.

In the oncology segment, key products include Kisqali for breast cancer, Pluvicto for metastatic prostate cancer and Scemblix for chronic myeloid leukemia, which have been highlighted as important near- and mid-term growth drivers, according to Novartis Innovative Medicines report 2023 as of 02/29/2024.

Management has identified a set of “growth brands” that together are expected to drive a large share of incremental sales, with Entresto, Cosentyx, Kisqali, Kesimpta and Pluvicto central to this strategy, according to Novartis Capital Markets Day materials as of 12/2022.

Looking at regional exposure, the United States is a core market for Novartis, accounting for a substantial portion of Innovative Medicines revenue in 2023, reflecting the importance of US pricing and reimbursement dynamics for the group’s earnings profile, according to Novartis operating results 2023 as of 02/29/2024.

In addition to marketed brands, Novartis’ late-stage pipeline spans indications such as cardiovascular disease, immunology, solid tumors and hematology, with multiple phase III programs that could become future revenue streams if successfully approved, according to Novartis pipeline overview as of 05/2026.

The company’s business is also shaped by the patent cycle, with some mature products facing generic or biosimilar competition and newer launches intended to offset these headwinds, a pattern highlighted in the discussion of patent expiries and lifecycle management in the 2023 annual report, according to Novartis risk review 2023 as of 02/29/2024.

Beyond individual drugs, Novartis increasingly emphasizes platforms such as radioligand therapies, gene therapies and RNA-targeted medicines as longer-term growth areas, reflecting a strategy to be positioned in modalities that could reshape standards of care in certain diseases, according to Novartis corporate overview as of 2024.

From a financial perspective, the company reported solid revenue and core operating income growth for full-year 2023, supported by demand for key brands and a focus on productivity, while also returning capital to shareholders through dividends and share buybacks, according to Novartis full-year 2023 results release as of 01/31/2024.

For investors watching the stock, the mix of established blockbusters, newer launches and pipeline assets, alongside cost discipline and capital returns, remains central to assessing how Novartis can sustain growth and profitability in a competitive global pharmaceuticals landscape, according to MarketBeat Novartis overview as of 06/08/2026.

Why Novartis AG matters for US investors

For US investors, Novartis is accessible via American depositary shares listed on the NYSE under the ticker NVS, providing exposure to a large-cap European healthcare name with significant operations and revenue in the United States, according to NYSE listing information as of 06/2026.

The group’s earnings are sensitive to US policy developments, including Medicare drug pricing reforms and broader discussions on healthcare costs, because a notable share of its sales comes from US payers and patients, according to Novartis risk review 2023 as of 02/29/2024.

In portfolio terms, Novartis can serve as a defensive component due to the generally non-cyclical nature of demand for prescription medicines, while still offering exposure to innovation cycles in areas such as oncology and immunology that can drive long-term growth, according to Novartis performance overview 2023 as of 02/29/2024.

In addition, the company’s dividend policy and history of regular shareholder returns are factors some US income-focused investors monitor closely when considering large international pharma stocks, according to Novartis dividend information as of 03/2024.

Conclusion

Novartis AG has reshaped itself into a focused innovative medicines player following the Sandoz spin-off and continues to lean on a portfolio of large growth brands and a broad late-stage pipeline to support future revenue. The company’s strong presence in the US market ties its earnings profile to American healthcare trends and policy shifts, while its NYSE listing makes it straightforward for US-based investors to gain exposure. At the same time, factors such as patent expiries, regulatory scrutiny on drug pricing and competitive dynamics across key therapeutic areas remain important variables for assessing the risk and opportunity profile of the stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.